Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
This multicenter, open-label, phase II study evaluated the safety and clinical activity of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, 2, and 3, in patients with metastatic melanoma.
Pharmacology, Toxicology and Pharmaceutical Science
5
8%
Biochemistry, Genetics and Molecular Biology
3
5%
Nursing and Health Professions
2
3%
Other
4
7%
Unknown
13
22%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2011.
All research outputs
#13,858,486
of 22,653,392 outputs
Outputs from Clinical Cancer Research
#9,648
of 12,561 outputs
Outputs of similar age
#151,467
of 239,688 outputs
Outputs of similar age from Clinical Cancer Research
#75
of 99 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,561 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,688 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
